Nuvation Bio's Iptrozy: First-Line ROS1 Cancer Treatment

Nuvation Bios Q1 2026 earnings report highlights Iptrozys success in ROS1-positive lung cancer treatment. New patient starts remained steady, but revenue surged to $18.5M from $15.7M, driven by a significant increase in first-line TKI-naive patients. Clinical data shows promising results, with updated TRUST studies indicating a median duration of response of over four years in treatment-naive patients. Safety remains strong, with minimal adverse event discontinuations. Nuvation Bio was added to NCCN guidelines for brain metastases, and physicians and key opinion leaders praise its durability and real-world tolerability. The pipeline also progresses, with safusitinib showing promising results in IDH1-mutant gliomas. Nuvation Bios cash pile stands at $533.7M, funding its launch and expansion without new financing. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/bcdfc9d04232357e